FDA
-
-
-
-
-
-
-
Cingulate Presents Positive Phase 3 Results for CTx-1301 Demonstrating Statistically Significant Efficacy and Entire Active-Day Symptom Control
-
-
-
-
-
-
-
Cingulate places CEO on administrative leave, names interim leadership
-
-
-
-
-
-
-
Cingulate Appoints Nilay Patel as Chief Legal Officer to Support Growth ahead of New Drug Application
-
-
-
-
-
-
-
Cingulate Inc (CING) Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-1301
-
-
-
-
-
-
-
Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market
-
-
-
-
-
-
-
FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD
-
-
-
-
-
-
-
Cingulate (CING) Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

